News
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
May 19th 2022The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc
May 19th 2022The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
May 18th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis
May 17th 2022The blood test from Diadem SpA, which quantifies the AZ 284 peptide as readout of U-p53AZ, showed a significantly higher AUC in both time-independent and time-dependent prognostic analyses than gold standard testing.
Adding Experience to the National Health Institute Council: Amy Brin, MSN, MA, PCNS-BC
May 17th 2022The chief executive officer of the Child Neurology Foundation provided insight on her new position at the National Health Institute’s National Advisory Neurological Disorders and Stroke Council. [WATCH TIME: 4 minutes]
Cognitive Functioning and Motor Difficulties Identified in Spinal Muscular Atrophy Type 3
May 16th 2022When compared with healthy controls, patients with SMA type 3 performed worse on tests that assessed executive function, language, and visuospatial abilities, suggesting that intrinsic brain pathology may exist in these patients.
AUPN 2022 Spring Chairs Session: Simulations for Training in Neurology
May 16th 2022David G. Standaert, MD, PhD; Wolfgang Muhlhofer, MD; and Latisha Sharma, MD, share their experience in applying simulation-based learning in Neurology and will discuss the current state and future potential of this approach. [WATCH TIME: 1 hour, 25 minutes]
Advocacy’s Part in the Progress in ALS: Matthew B. Harms, MD
May 16th 2022In light of ALS Awareness Month, the associate professor of neurology at Columbia University discussed the ways in which advocacy has provided a platform for patients and improved conversations in care. [WATCH TIME: 6 minutes]
The Potential of Sleepio and CBT in the Poststroke Recovery Process
May 14th 2022The cofounder and chief scientist at Big Health and professor of sleep medicine at the University of Oxford discussed the recent findings of a study of Sleepio in poststroke rehabilitation and the role that cognitive behavioral therapy could play in that care process.
An AI Morphology Array’s Potential to Improve Parkinson Diagnosis
May 13th 2022John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.
The Role of Genetics and Database Variety for ALS Research: Matthew B. Harms, MD
May 13th 2022The associate professor of neurology at Columbia University discussed the role of genetics in ALS and how it compares to other neurodegenerative disorders, as well as why having a variety of large databases will prove positive for the field. [WATCH TIME: 4 minutes]
Digital CBT Tool Sleepio Improves Sleep in Patients Undergoing Poststroke Rehabilitation
May 12th 2022The digital cognitive behavioral therapy improved sleep for almost half of the study cohort and showed additional signs of improvement for depression and anxiety among individuals in rehabilitation for stroke.
